NASDAQ:IMTXW Immatics (IMTXW) Stock Price, News & Analysis → This Could be Your “Big Money” AI Moment (From InvestorPlace) (Ad) Free IMTXW Stock Alerts $2.20 -0.10 (-4.35%) (As of 05/21/2024 ET) Add Compare Share Share Today's Range$2.18▼$2.2050-Day Range$2.12▼$3.7552-Week Range$1.60▼$4.14Volume19,402 shsAverage Volume6,145 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsOwnershipSEC FilingsShort InterestSocial Media Get Immatics alerts: Email Address Ad InvestorPlaceThis Could be Your “Big Money” AI MomentBREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. About Immatics Stock (NASDAQ:IMTXW)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTXW Stock News HeadlinesMay 11, 2024 | americanbankingnews.comImmatics (NASDAQ:IMTXW) Trading Down 0.4%November 30, 2023 | finance.yahoo.comLevicept Appoints Eliot Forster as CEONovember 2, 2023 | finance.yahoo.comImmatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth PlansOctober 31, 2023 | morningstar.comAdaptive Biotechnologies Corp ADPTSeptember 23, 2023 | finance.yahoo.comImmatics N.V. (NASDAQ:IMTX) is definitely on the radar of institutional investors who own 47% of the companySee More Headlines Receive IMTXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:IMTXW CUSIPN/A CIK1809196 Webimmatics.com Phone4970715397700FaxN/AEmployees432Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$74.47 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 49)CEO, MD, Member of Management Board & Executive Director Comp: $883.18kDr. Toni Weinschenk Ph.D. (Age 50)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 58)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 47)Chief Operations Officer Mr. Edward A. Sturchio J.D. (Age 48)General Counsel & Secretary Dr. Carsten Reinhardt M.D. (Age 57)Ph.D., Chief Development Officer Mr. Cedrik M. Britten M.D. (Age 48)Chief Medical Officer Mr. Jordan Silverstein (Age 44)Head of Strategy Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Ephraim Hofsäß M.Sc.Vice President of SEC Reporting & AccountingMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors IMTXW Stock Analysis - Frequently Asked Questions How have IMTXW shares performed in 2024? Immatics' stock was trading at $2.92 at the beginning of 2024. Since then, IMTXW stock has decreased by 24.7% and is now trading at $2.20. View the best growth stocks for 2024 here. How do I buy shares of Immatics? Shares of IMTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMTXW) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.